


Product Information



ML-9

Item No. 10010236

CAS Registry No.: 105637-50-1
Formal Name: 1-[(5-chloro-1-naphthalenyl)sulfonyl]
hexahydro-1H-1,4-diazepine,
monohydrochloride
MF: C₁₅H₁₇ClN₂O₂S • HCl
FW: 361.3
Purity: ≥98%
Stability: ≥2 years at -20°C
Supplied as: A crystalline solid
UV/Vis.: λ_{max}: 229, 300 nm



Laboratory Procedures

For long term storage, we suggest that ML-9 be stored as supplied at -20°C. It will be stable for at least two years.

ML-9 is supplied as a crystalline solid. A stock solution may be made by dissolving the ML-9 in an organic solvent purged with an inert gas. ML-9 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of ML-9 in ethanol is approximately 0.5 mg/ml and approximately 30 mg/ml in DMSO and DMF.

ML-9 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ML-9 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. ML-9 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

ML-9 was originally identified as a selective Ca²⁺-calmodulin-dependent myosin light chain kinase inhibitor. Concentrations from 10-100 μM are effective at inhibiting vascular smooth muscle tension and reducing intracellular Ca²⁺ concentrations.¹ ML-9 also inhibits PKB/Akt activity with an IC₅₀ range of 10-50 μM in rat primary adipocytes. This results in a specific inhibition of insulin-stimulated glucose transport and GLUT4/IGF II receptor translocation to the plasma membrane yet does not interfere with the antilipolytic effect of insulin.² Additionally, ML-9 inhibits other serine/threonine kinases including PKA (IC₅₀ = ~20 μM), p90 S6 (IC₅₀ = ~50 μM), and MAP kinase (IC₅₀ = ~35 μM).²

References

1. Ito, S., Kume, H., Honjo, H., *et al.* ML-9, a myosin light chain kinase inhibitor, reduces intracellular Ca²⁺ concentration in guinea pig trachealis. *Eur. J. Pharmacol.* **486**, 325-333 (2004).
2. Smith, U., Carvalho, E., Mosialou, E., *et al.* PBK inhibition prevents the stimulatory effect of insulin on glucose transport and protein translocation but not the antilipolytic effect in rat adipocytes. *Biochem. Biophys. Res. Commun.* **268**, 315-320 (2000).

Related Products

For a list of related products please visit: www.caymanchem.com/catalog/10010236

Cayman Chemical

Mailing address

1180 E. Ellsworth Road
Ann Arbor, MI
48108 USA

Phone

(800) 364-9897
(734) 971-3335

Fax

(734) 971-3640

E-Mail

custserv@caymanchem.com

Web

www.caymanchem.com

WARNING: THIS PRODUCT IS FOR LABORATORY RESEARCH ONLY: NOT FOR ADMINISTRATION TO HUMANS. NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

MATERIAL SAFETY DATA

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Material Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes no warranty or guarantee of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman warrants only to the original customer that the material will meet our specifications at the time of delivery.

Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have any obligation or liability, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees.

Buyer's exclusive remedy and Cayman's sole liability hereunder shall be limited to a refund of the purchase price, or at Cayman's option, the replacement, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our Warranty and Limitation of Remedy located on our website and in our catalog.

Copyright Cayman Chemical Company, 04/03/2012